DW-MRI as a biomarker to compare therapeutic outcomes in radiotherapy regimens incorporating temozolomide or gemcitabine in glioblastoma.

DW-MRI as a biomarker to compare therapeutic outcomes in radiotherapy regimens incorporating temozolomide or gemcitabine in glioblastoma.

The effectiveness of the radiosensitizer gemcitabine (GEM) was evaluated in a mouse glioma along with the imaging biomarker diffusion-weighted magnetic resonance imaging (DW-MRI) for early detection of treatment effects. A genetically engineered murine GBM model [Ink4a-Arf(-/-) Pten(loxP/loxP)/Ntv-a...

Full description

Bibliographic Details
Main Authors: Stefanie Galbán, Benjamin Lemasson, Terence M Williams, Fei Li, Kevin A Heist, Timothy D Johnson, Judith S Leopold, Thomas L Chenevert, Theodore S Lawrence, Alnawaz Rehemtulla, Tom Mikkelsen, Eric C Holland, Craig J Galbán, Brian D Ross
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3334987?pdf=render

Internet

http://europepmc.org/articles/PMC3334987?pdf=render

Similar Items